Mark Eccleston PhD, MBA

Business Development Director

New Dr Mark Eccleston

Dr Mark Eccleston is an enthusiastic and passionate biotechnology entrepreneur with over 20 years experience in the sector. He holds a PhD in Polymer Chemistry for biomedical applications and gained an MBA (entrepreneurship) from the University of Dundee in 2008.

Mark is the Managing Director of OncoLytika Ltd. a technical consultancy company working with international private and public limited companies operating in the diagnostics and therapeutic sectors as well as academia.

Dr Eccleston is the Business Development Director at Volition, a company developing next generation blood tests for early detection of cancer. Volition’s epigenetics based immunoassay approach to rapid, affordable cancer diagnostics is intended to revolutionise cancer screening and diagnosis. Mark coordinates the commercialisation of Volition’s Research Use kit range based on this proprietary Nucleosomics® technology platform. 

" It is tremendously rewarding working on such a cutting-edge technology – one that has the potential to not only help diagnose cancer, but also potentially many other conditions."